Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM17 in Moderate to Severe Atopic Dermatitis
NCT07445919Phase 2Recruiting
- Sponsor
- SinoMab BioScience Limited
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SM17 in atopic dermatitis (AD), sponsored by SinoMab BioScience Limited. Started Mar 2026; status: recruiting.
02
Drugs
SM17
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07445919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445919.